adalimumab,infliximab
abbvie,janssen
['adalimumab']
outstanding presentation by data from #proprd regarding 12 month remission and treatment patterns in #cd of the #pouch 57% of patients in remission
no difference in remission by treatment switching patterns #ddw23 
Assistant Professor, Associate Program Director, GI & Hepatology Fellowship @UNCGastro | Research & Clinical interest in #IBD, #pouchitis, outcomes after #IPAA